EWA
NPCE icon

EverSource Wealth Advisors’s Neuropace NPCE Stock Holding History

EverSource Wealth Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$794 Buy
50
+32
+178% +$515 ﹤0.01% 4037
2026
Q1 		$237 Buy
+18
New +$270 ﹤0.01% 4182

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EverSource Wealth Advisors's NPCE Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Neuropace (NPCE) stake by 178% in Q2 2026, buying an estimated $515 and bringing the position to 50 shares worth $794. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

EverSource Wealth Advisors first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • EverSource Wealth Advisors held 50 shares of Neuropace worth $794 as of Q2 2026.
  • EverSource Wealth Advisors bought 32 Neuropace shares in Q2 2026, an estimated $515.
  • Neuropace made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4037 holding.
  • EverSource Wealth Advisors first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.